Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer

• Status: Completed
• Trial end date: 2016-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if Cediranib when added to chemotherapy is more effective than chemotherapy alone in prolonging life expectancy and slowing disease progression in patients with previously untreated metastatic colorectal cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Capecitabine; Cediranib; Fluorouracil; Leucovorin; Levoleucovorin; Oxaliplatin

Criteria

Inclusion Criteria:

• Written Informed Consent

• Carcinoma of the colon or rectum

• One or more measurable lesions

Exclusion Criteria:

• Adjuvant/neoadjuvant therapy within 6-12 months of study entry

• Untreated unstable brain or meningeal metastases

• Specific laboratory ranges

• Specific cardiovascular problems

• Participation in other trials within 30 days